Global Advanced Therapy Medicinal Products Market – our new study reveals trends, R&D progress, and predicted revenues
How will the global ATMP industry evolve during the forecast period from 2021-2031? If you are involved in this sector you must read this newly updated report. As the report provides details about the commercial trends, market shares, industrial activities, revenues, economic and social landscapes and other factors. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities and business prospects there. In addition, the report would also help you to enhance your strategic decision making, strengthen the analysis of competitors, allows you to formulate growth strategies, and maximise profitability of the company.
Discover how to stay ahead
Our 380 pages report provides 226 tables and 211 charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing ATMP Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), STEP Analysis, Supply Chain Analysis, product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Global ATMP Market: By Therapy Products
• Cell Therapy Products
• Gene Therapy Products
• CAR-T Therapy Products
• Tissue Engineered Products
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
– U.S.
– Canada
• Europe
– Germany
– France
– United Kingdom
– Italy
– Spain
– Rest of Europe
• Asia Pacific
– China
– Japan
– India
– Rest of Asia Pacific
• Latin America
– Brazil
– Mexico
– Rest of Latin America
• Middle East and Africa
– UAE
– Africa
– Rest of Middle East and Africa
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Global ATMP Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for ATMP Market will surpass $xx billion in 2021, our work calculates it grow in near future. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Global ATMP Market report helps you
In summary, our 380 page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Global ATMP Market, with forecasts for Therapy Products, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the ATMP market in North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 12 of the major companies involved in the Global ATMP Market. Some of the company’s profiled in this report include Bluebird bio, Inc., Gilead Sciences, Inc., JCR Pharmaceuticals, Co. Ltd., MEDIPOST, PHARMICELL Co. Ltd., Spark Therapeutics, Vericel Corporation and others.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Global ATMP Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031: Forecasts by Therapy Products (Cell Therapy Products, Gene Therapy Products, CAR-T Therapy Products and Tissue Engineered Products). Regional and Leading National Market Analysis PLUS Analysis of Leading ATMP Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Global Advanced Therapy Medicinal Products Market Overview
1.2. Global Advanced Therapy Medicinal Products Market Segmentation
1.3. Why You Should Read This Report
1.4. How This Report Delivers
1.5. Key Questions Answered by This Analytical Report
1.6. Who is This Report For?
1.7. Methodology
1.8. Frequently Asked Questions (FAQ)
1.9. Associated Visiongain Reports
1.10. About Visiongain
2. Executive Summary
3. Introduction to ATMP Market
3.1. ATMP: Market Segmentation
3.1.1. Cell Therapy Products
3.1.2. Gene Therapy Products
3.1.3. CAR-T Therapy Products
3.1.4. Tissue Engineered Products
3.2. Market Dynamics: Global ATMP Market
3.2.1. Drivers
3.2.1.1. Rising preference for advanced therapies
3.2.1.2. Rising prevalence of chronic and genetic disorders
3.2.1.3. Increasing number of clinical trials in ATMP segment
3.2.1.4. Rising demand for organ transplantation
3.2.2. Restraints
3.2.2.1. High cost of therapy products
3.2.2.2. Stringent regulatory norms
3.2.3. Opportunities
3.2.3.1. Increasing health benefits
3.2.3.2. Growing economies and demographics in Asia-Pacific
3.2.3.3. Rising applications of ATMP in various indications
3.2.3.3.1. Ageing increases the risk for Alzheimer’s
3.2.3.3.2. Increasing development for the treatment of Cystic Fibrosis
3.2.3.3.3. Increasing number of clinical trials for the treatment of Muscular Dystrophies
3.2.3.3.4. Rising prevalence of Hemophilia
3.3. Approved ATMPs 2015-2019
3.4. STEP Analysis: Global ATMP Market
3.4.1. Social Factors Impacting the ATMP Market
3.4.2. Technological Factors Impacting the ATMP Market
3.4.3. Economical Factors Impacting the ATMP Market
3.4.4. Political Factors Impacting the ATMP Market
3.5. Supply Chain: Global ATMP Market
3.6. Regulatory Environment: ATMP
3.7. Trends in Global ATMP Market 2020
3.8. Impact of Coronavirus (COVID-19)
3.8.1. Possible impact scenarios of COVID-19
3.8.1.1. ‘V’ shaped recovery model
3.8.1.2. ‘U’ shaped recovery model
3.8.1.3. ‘L’ shaped recovery model
3.8.1.4. ‘W’ shaped recovery model
3.8.1.5. Conclusion
4. Global Advanced Therapy Medicinal Products Market by Therapy Products, 2020-2031
4.1. Leading Advanced Therapy Medicinal Products Market, by Therapy Products in 2021
4.2. Global ATMP Market, by Therapy Products – Coronavirus Impact Scenario
4.2.1. Global ATMP Market, by Therapy Products (V – Shaped Recovery Model)
4.2.2. Global ATMP Market, by Therapy Products (U - Shaped Recovery Model)
4.2.3. Global ATMP Market, by Therapy Products (L - Shaped Recovery Model)
4.2.4. Global ATMP Market, by Therapy Products (W - Shaped Recovery Model)
4.3. Cell Therapy Products
4.3.1. Cell Therapy Products Market – Coronavirus Impact Scenario
4.3.1.1. ‘V’ Shaped Recovery Model
4.3.1.2. ‘U’ Shaped Recovery Model
4.3.1.3. ‘L’ Shaped Recovery Model
4.3.1.4. ‘W’ Shaped Recovery Model
4.4. Gene Therapy Products
4.4.1. Gene Therapy Products Market – Coronavirus Impact Scenario
4.4.1.1. ‘V’ Shaped Recovery Model
4.4.1.2. ‘U’ Shaped Recovery Model
4.4.1.3. ‘L’ Shaped Recovery Model
4.4.1.4. ‘W’ Shaped Recovery Model
4.5. CAR-T Therapy Products
4.5.1. CAR-T Therapy Products Market – Coronavirus Impact Scenario
4.5.1.1. ‘V’ Shaped Recovery Model
4.5.1.2. ‘U’ Shaped Recovery Model
4.5.1.3. ‘L’ Shaped Recovery Model
4.5.1.4. ‘W’ Shaped Recovery Model
4.6. Tissue Engineered Products
4.6.1. Tissue Engineered Products Market – Coronavirus Impact Scenario
4.6.1.1. ‘V’ Shaped Recovery Model
4.6.1.2. ‘U’ Shaped Recovery Model
4.6.1.3. ‘L’ Shaped Recovery Model
4.6.1.4. ‘W’ Shaped Recovery Model
5. Global ATMP Market by Regions, 2020-2031
5.1. The ATMP Market Overview
5.2. Segmenting the Global ATMP Market
5.2.1. Changes in the Global ATMP Market Share – 2020, 2026 and 2031
5.3. Global ATMP Market, by Geography – Coronavirus Impact Scenario
5.3.1. ‘V’ Shaped Recovery Model
5.3.2. ‘U’ Shaped Recovery Model
5.3.3. ‘L’ Shaped Recovery Model
5.3.4. ‘W’ Shaped Recovery Model
6. North America ATMP Market
6.1. North America ATMP Market by Therapy Product
6.2. North America ATMP Market by Therapy Product (V – Shaped Recovery Model)
6.3. North America ATMP Market by Therapy Product (U – Shaped Recovery Model)
6.4. North America ATMP Market by Therapy Product (L – Shaped Recovery Model)
6.5. North America ATMP Market by Therapy Product (W – Shaped Recovery Model)
6.6. North America ATMP Market by Country
6.7. North America ATMP Market, Coronavirus Impact Scenario
6.7.1. ‘V’ Shaped Recovery Model
6.7.2. ‘U’ Shaped Recovery Model
6.7.3. ‘L’ Shaped Recovery Model
6.7.4. ‘W’ Shaped Recovery Model
6.7.5. Growing Demand for Clinical Trials in U.S. to Augur Market Growth
6.7.5.1. U.S. ATMP Market Forecast, 2021-2031
6.7.5.2. U.S. ATMP Market, Coronavirus Impact Scenario
6.7.5.2.1. ‘V’ Shaped Recovery Model
6.7.5.2.2. ‘U’ Shaped Recovery Model
6.7.5.2.3. ‘L’ Shaped Recovery Model
6.7.5.2.4. ‘W’ Shaped Recovery Model
6.7.6. Rising government support drives the growth in Canada
6.7.6.1. Canada ATMP Market, Coronavirus Impact Scenario
6.7.6.1.1. ‘V’ Shaped Recovery Model
6.7.6.1.2. ‘U’ Shaped Recovery Model
6.7.6.1.3. ‘L’ Shaped Recovery Model
6.7.6.1.4. ‘W’ Shaped Recovery Model
7. Europe
7.1. Market Authorisations in Europe
7.2. Europe ATMP Market by Product
7.3. Europe ATMP Market by Therapy Product (V – Shaped Recovery Model)
7.4. Europe ATMP Market by Therapy Product (U – Shaped Recovery Model)
7.5. Europe ATMP Market by Therapy Product (L – Shaped Recovery Model)
7.6. Europe ATMP Market by Therapy Product (W – Shaped Recovery Model)
7.7. Europe ATMP Market by Country
7.8. Europe ATMP Market, by Country - Coronavirus Impact Scenario
7.8.1. ‘V’ Shaped Recovery Model
7.8.2. ‘U’ Shaped Recovery Model
7.8.3. ‘L’ Shaped Recovery Model
7.8.4. ‘W’ Shaped Recovery Model
7.8.5. Increasing number of ATMPs in Germany propels the market growth
7.8.5.1. Germany ATMP Market, Coronavirus Impact Scenario
7.8.5.1.1. ‘V’ Shaped Recovery Model
7.8.5.1.2. ‘U’ Shaped Recovery Model
7.8.5.1.3. ‘L’ Shaped Recovery Model
7.8.5.1.4. ‘W’ Shaped Recovery Model
7.8.6. Increasing access to ATMP in the U.K. drives the market
7.8.6.1. U.K. ATMP Market, Coronavirus Impact Scenario
7.8.6.1.1. ‘V’ Shaped Recovery Model
7.8.6.1.2. ‘U’ Shaped Recovery Model
7.8.6.1.3. ‘L’ Shaped Recovery Model
7.8.6.1.4. ‘W’ Shaped Recovery Model
7.8.7. Growing popularity of ATMP in France propels the market growth
7.8.7.1. France ATMP Market, Coronavirus Impact Scenario
7.8.7.1.1. ‘V’ Shaped Recovery Model
7.8.7.1.2. ‘U’ Shaped Recovery Model
7.8.7.1.3. ‘L’ Shaped Recovery Model
7.8.7.1.4. ‘W’ Shaped Recovery Model
7.8.8. Increasing number of clinical trials in Italy is one of the prominent factors for the growth of ATMP
7.8.8.1. Italy ATMP Market, Coronavirus Impact Scenario
7.8.8.1.1. ‘V’ Shaped Recovery Model
7.8.8.1.2. ‘U’ Shaped Recovery Model
7.8.8.1.3. ‘L’ Shaped Recovery Model
7.8.8.1.4. ‘W’ Shaped Recovery Model
7.8.9. Favourable government regulations in Spain supports the market growth
7.8.9.1. Spain ATMP Market, Coronavirus Impact Scenario
7.8.9.1.1. ‘V’ Shaped Recovery Model
7.8.9.1.2. ‘U’ Shaped Recovery Model
7.8.9.1.3. ‘L’ Shaped Recovery Model
7.8.9.1.4. ‘W’ Shaped Recovery Model
7.8.10. Rest of Europe
7.8.10.1. Rest of Europe ATMP Market, Coronavirus Impact Scenario
7.8.10.1.1. ‘V’ Shaped Recovery Model
7.8.10.1.2. ‘U’ Shaped Recovery Model
7.8.10.1.3. ‘L’ Shaped Recovery Model
7.8.10.1.4. ‘W’ Shaped Recovery Model
8. Asia-Pacific
8.1. Asia-Pacific ATMP Market by Therapy Product
8.2. Asia-Pacific ATMP Market by Therapy Product (V – Shaped Recovery Model)
8.3. Asia-Pacific ATMP Market by Therapy Product (U – Shaped Recovery Model)
8.4. Asia-Pacific ATMP Market by Therapy Product (L – Shaped Recovery Model)
8.5. Asia-Pacific ATMP Market by Therapy Product (W – Shaped Recovery Model)
8.6. Asia-Pacific ATMP Market by Country
8.7. Asia-Pacific ATMP Market, Coronavirus Impact Scenario
8.7.1. ‘V’ Shaped Recovery Model
8.7.2. ‘U’ Shaped Recovery Model
8.7.3. ‘L’ Shaped Recovery Model
8.7.4. ‘W’ Shaped Recovery Model
8.7.5. Increasing healthcare spending in Japan propels the market growth
8.7.5.1. Japan ATMP Market, Coronavirus Impact Scenario
8.7.5.1.1. ‘V’ Shaped Recovery Model
8.7.5.1.2. ‘U’ Shaped Recovery Model
8.7.5.1.3. ‘L’ Shaped Recovery Model
8.7.5.1.4. ‘W’ Shaped Recovery Model
8.7.6. Rising research and development investments supports the growth in China
8.7.6.1. China ATMP Market, Coronavirus Impact Scenario
8.7.6.1.1. ‘V’ Shaped Recovery Model
8.7.6.1.2. ‘U’ Shaped Recovery Model
8.7.6.1.3. ‘L’ Shaped Recovery Model
8.7.6.1.4. ‘W’ Shaped Recovery Model
8.7.7. Growing healthcare awareness in India drive the market growth
8.7.7.1. India ATMP Market, Coronavirus Impact Scenario
8.7.7.1.1. ‘V’ Shaped Recovery Model
8.7.7.1.2. ‘U’ Shaped Recovery Model
8.7.7.1.3. ‘L’ Shaped Recovery Model
8.7.7.1.4. ‘W’ Shaped Recovery Model
8.7.8. Rest of Asia-Pacific
8.7.8.1. Rest of Asia-Pacific ATMP Market, Coronavirus Impact Scenario
8.7.8.1.1. ‘V’ Shaped Recovery Model
8.7.8.1.2. ‘U’ Shaped Recovery Model
8.7.8.1.3. ‘L’ Shaped Recovery Model
8.7.8.1.4. ‘W’ Shaped Recovery Model
9. Latin America
9.1. Latin America ATMP Market by Therapy Product
9.2. Latin America ATMP Market by Therapy Product (V – Shaped Recovery Model)
9.3. Latin America ATMP Market by Therapy Product (U – Shaped Recovery Model)
9.4. Latin America ATMP Market by Therapy Product (L – Shaped Recovery Model)
9.5. Latin America ATMP Market by Therapy Product (W – Shaped Recovery Model)
9.6. Latin America ATMP Market by Country
9.7. Latin America ATMP Market, Coronavirus Impact Scenario
9.7.1. ‘V’ Shaped Recovery Model
9.7.2. ‘U’ Shaped Recovery Model
9.7.3. ‘L’ Shaped Recovery Model
9.7.4. ‘W’ Shaped Recovery Model
9.7.5. Rising number of trials registered in Brazil supports the market growth
9.7.5.1. Brazil ATMP Market, Coronavirus Impact Scenario
9.7.5.1.1. ‘V’ Shaped Recovery Model
9.7.5.1.2. ‘U’ Shaped Recovery Model
9.7.5.1.3. ‘L’ Shaped Recovery Model
9.7.5.1.4. ‘W’ Shaped Recovery Model
9.7.6. Technological advancements in Mexico propels the growth
9.7.6.1. Mexico ATMP Market, Coronavirus Impact Scenario
9.7.6.1.1. ‘V’ Shaped Recovery Model
9.7.6.1.2. ‘U’ Shaped Recovery Model
9.7.6.1.3. ‘L’ Shaped Recovery Model
9.7.6.1.4. ‘W’ Shaped Recovery Model
9.7.7. Rest of Latin America
9.7.7.1. Rest of Latin America ATMP Market, Coronavirus Impact Scenario
9.7.7.1.1. ‘V’ Shaped Recovery Model
9.7.7.1.2. ‘U’ Shaped Recovery Model
9.7.7.1.3. ‘L’ Shaped Recovery Model
9.7.7.1.4. ‘W’ Shaped Recovery Model
10. Middle-East & Africa
10.1. MEA ATMP Market by Therapy Products
10.2. MEA ATMP Market by Therapy Product (V – Shaped Recovery Model)
10.3. MEA ATMP Market by Therapy Product (U – Shaped Recovery Model)
10.4. MEA ATMP Market by Therapy Product (L – Shaped Recovery Model)
10.5. MEA ATMP Market by Therapy Product (W – Shaped Recovery Model)
10.6. MEA ATMP Market by Country
10.7. MEA ATMP Market, Coronavirus Impact Scenario
10.7.1. ‘V’ Shaped Recovery Model
10.7.2. ‘U’ Shaped Recovery Model
10.7.3. ‘L’ Shaped Recovery Model
10.7.4. ‘W’ Shaped Recovery Model
10.7.5. Rising demand for healthcare products in UAE supports the market growth
10.7.5.1. UAE ATMP Market, Coronavirus Impact Scenario
10.7.5.1.1. ‘V’ Shaped Recovery Model
10.7.5.1.2. ‘U’ Shaped Recovery Model
10.7.5.1.3. ‘L’ Shaped Recovery Model
10.7.5.1.4. ‘W’ Shaped Recovery Model
10.7.6. Increasing healthcare spending in South Africa drives the market growth
10.7.6.1. South Africa ATMP Market, Coronavirus Impact Scenario
10.7.6.1.1. ‘V’ Shaped Recovery Model
10.7.6.1.2. ‘U’ Shaped Recovery Model
10.7.6.1.3. ‘L’ Shaped Recovery Model
10.7.6.1.4. ‘W’ Shaped Recovery Model
10.7.7. Rest of MEA
10.7.7.1. Rest of MEA ATMP Market, Coronavirus Impact Scenario
10.7.7.1.1. ‘V’ Shaped Recovery Model
10.7.7.1.2. ‘U’ Shaped Recovery Model
10.7.7.1.3. ‘L’ Shaped Recovery Model
10.7.7.1.4. ‘W’ Shaped Recovery Model
11. Market Analysis
11.1. Company Share Analysis, 2020
12. Company Profiles
12.1. Bluebird bio, Inc.
12.1.1. Company Overview
12.1.2. Company Snapshot, 2020
12.1.3. Financial Outlook, 2015-2019
12.1.4. Product Portfolio
12.1.5. Strategic Developments, 2019-2020
12.2. Bristol Myers-Squibb (Celgene Corporation)
12.2.1. Company Overview
12.2.2. Company Snapshot
12.2.3. Financial Outlook, 2015-2019
12.2.4. Product Portfolio
12.2.5. Strategic Developments, 2019
12.3. Gilead Sciences, Inc.
12.3.1. Company Overview
12.3.2. Company Snapshot
12.3.3. Financial Outlook, 2015-2019
12.3.4. Product Portfolio
12.3.5. Strategic Developments, 2020
12.4. JCR Pharmaceuticals Co., Ltd.
12.4.1. Company Overview
12.4.2. Company Outlook
12.4.3. Financial Outlook, 2015-2019
12.4.4. Product Portfolio
12.4.5. Strategic Developments, 2018
12.5. Kolon TissueGene, Inc.
12.5.1. Company Overview
12.5.2. Company Snapshot
12.5.3. Product Portfolio
12.5.4. Strategic Developments, 2018-2020
12.6. MEDIPOST
12.6.1. Company Overview
12.6.2. Company Snapshot
12.6.3. Financial Outlook, 2017-2019
12.6.4. Product Portfolio
12.6.5. Strategic Developments, 2018-2020
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Company Snapshot
12.7.3. Financial Outlook, 2015-2019
12.7.4. Product Portfolio
12.7.5. Strategic Developments, 2018-2020
12.8. Organogenesis Holdings, Inc.
12.8.1. Company Overview
12.8.2. Company Snapshot
12.8.3. Financial Outlook, 2017-2019
12.8.4. Product Portfolio
12.9. PHARMICELL Co., Ltd.
12.9.1. Company Overview
12.9.2. Company Snapshot
12.9.3. Product Portfolio
12.10. Spark Therapeutics, Inc.
12.10.1. Company Overview
12.10.2. Company Snapshot
12.10.3. Product Portfolio
12.10.4. Strategic Developments, 2018-2019
12.11. uniQure N.V.
12.11.1. Company Overview
12.11.2. Company Snapshot
12.11.3. Financial Outlook, 2015-2019
12.11.4. Product Portfolio
12.11.5. Strategic Developments, 2018-2019
12.12. Vericel Corporation
12.12.1. Company Overview
12.12.2. Company Snapshot
12.12.3. Financial Outlook, 2015-2019
12.12.4. Product Portfolio
12.12.5. Strategic Developments, 2018
13. Conclusion
13.1. Overview of the Current Market Conditions and Market Forecast, 2020-2031
13.2. Leading Global ATMP Market, by Therapy Product
13.3. Leading Regions in the Global ATMP Market
13.4. Recommendations
14. Glossary
15. List of Companies & Organisations
15.1. List of Companies
15.2. List of Organisations
List of Tables
TABLE 1 GLOBAL ATMP MARKET: REVENUE SNAPSHOT
TABLE 2 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V-SHAPED RECOVERY MODEL)
TABLE 3 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U-SHAPED RECOVERY MODEL)
TABLE 4 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L-SHAPED RECOVERY MODEL)
TABLE 5 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W-SHAPED RECOVERY MODEL)
TABLE 6 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS MARKET FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 7 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN) AND AGR (%), 2020-2031 (V-SHAPED RECOVERY MODEL)
TABLE 8 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
TABLE 9 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
TABLE 10 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
TABLE 11 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 12 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 13 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
TABLE 14 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
TABLE 15 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W SHAPED RECOVERY MODEL)
TABLE 16 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 17 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V SHAPED RECOVERY MODEL)
TABLE 18 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U SHAPED RECOVERY MODEL)
TABLE 19 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
TABLE 20 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W SHAPED RECOVERY MODEL)
TABLE 21 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 22 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V SHAPED RECOVERY MODEL)
TABLE 23 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U SHAPED RECOVERY MODEL)
TABLE 24 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
TABLE 25 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
TABLE 26 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 27 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
TABLE 28 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ MN), AGR (%) AND CAGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
TABLE 29 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
TABLE 30 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
TABLE 31 GLOBAL ATMP MARKET AND FORECAST, BY REGION MARKET FORECAST: REVENUE ($ BN), AGR (%), AND CAGR (%), 2020-2031
TABLE 32 GLOBAL ATMP MARKET AND FORECAST: MARKET SHARE BY REGION, 2021, 2026 AND 2031
TABLE 33 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 34 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 35 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 36 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 37 NORTH AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 38 NORTH AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V- SHAPED RECOVERY MODEL)
TABLE 39 NORTH AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U- SHAPED RECOVERY MODEL)
TABLE 40 NORTH AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L- SHAPED RECOVERY MODEL)
TABLE 41 NORTH AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
TABLE 42 NORTH AMERICA ATMP MARKET AND FORECAST: BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 43 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 44 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED MARKET RECOVERY MODEL)
TABLE 45 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 46 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 47 U.S. ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 48 U.S. ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 49 U.S. ATMP MARKET AND FORECAST, REVENUE ($ MN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 50 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 51 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 52 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 53 CANADA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 54 CANADA ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 55 CANADA ATMP MARKET AND FORECAST, REVENUE ($ B), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 56 CANADA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 57 CANADA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 58 CANADA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 59 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 60 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V- SHAPED RECOVERY MODEL)
TABLE 61 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U- SHAPED RECOVERY MODEL)
TABLE 62 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L- SHAPED RECOVERY MODEL)
TABLE 63 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
TABLE 64 EUROPE ATMP MARKET AND FORECAST: BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 65 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 66 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 67 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 68 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 69 GERMANY ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 70 GERMANY ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 71 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 72 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 73 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 74 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 75 U.K. ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 76 U.K. ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 77 U.K. ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 78 U.K. ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 79 U.K. ATMP MARKET AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 80 U.K. ATMP W-SHAPED MARKET SCENARIO AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 81 FRANCE ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 82 FRANCE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 83 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 84 FRANCE ATMP MARKET AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 85 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 86 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 87 ITALY ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 88 ITALY ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 89 ITALY ATMP MARKET AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 90 ITALY ATMP MARKET AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 91 ITALY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 92 ITALY ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 93 SPAIN ATMP MARKET AND FORECAST: REVENUE ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 94 SPAIN ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 95 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 96 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 97 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 98 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 99 REST OF EUROPE ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 100 REST OF EUROPE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 101 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 102 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 103 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 104 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 105 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 106 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V- SHAPED RECOVERY MODEL)
TABLE 107 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U- SHAPED RECOVERY MODEL)
TABLE 108 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L- SHAPED RECOVERY MODEL)
TABLE 109 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
TABLE 110 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 111 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 112 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 113 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 114 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 115 JAPAN ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 116 JAPAN ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 117 JAPAN ATMP MARKET AND FORECAST REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 118 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 119 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 120 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 121 CHINA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 122 CHINA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 123 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%),2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 124 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 125 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 126 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 127 INDIA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 128 INDIA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 129 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 130 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 131 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 132 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 133 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 134 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 135 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 136 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 137 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 138 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 139 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 140 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V- SHAPED RECOVERY MODEL)
TABLE 141 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U- SHAPED RECOVERY MODEL)
TABLE 142 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L- SHAPED RECOVERY MODEL)
TABLE 143 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
TABLE 144 LATIN AMERICA ATMP MARKET AND FORECAST: BY COUNTRY REVENUE ($ MN), AGR (%) AND CAGR (%), 2020-2031
TABLE 145 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 146 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 147 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 148 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 149 BRAZIL ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 150 BRAZIL ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 151 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 152 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 153 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 154 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 155 MEXICO ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 156 MEXICO ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 157 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 158 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 159 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-20301 (L – SHAPED RECOVERY MODEL)
TABLE 160 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 161 REST OF LATIN AMERICA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 162 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 163 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 164 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL
TABLE 165 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 166 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 167 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCTS, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 168 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V- SHAPED RECOVERY MODEL)
TABLE 169 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U- SHAPED RECOVERY MODEL)
TABLE 170 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L- SHAPED RECOVERY MODEL)
TABLE 171 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
TABLE 172 MEA ATMP MARKET AND FORECAST: BY COUNTRY REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 173 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 174 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 175 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 176 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 177 UAE ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 178 UAE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 179 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 180 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 181 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 182 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 183 SOUTH AFRICA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 184 SOUTH AFRICA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 185 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 186 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 187 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 188 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 189 REST OF MEA ATMP MARKET AND FORECAST: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 190 REST OF MEA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031
TABLE 191 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
TABLE 192 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
TABLE 193 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
TABLE 194 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), AGR (%) AND CAGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
TABLE 195 BLUEBIRD BIO, INC.: KEY FACTS, 2020
TABLE 196 BLUEBIRD BIO, INC.: HISTORICAL REVENUE ($ TH), 2015-2019
TABLE 197 BLUEBIRD BIO, INC.: STRATEGIC DEVELOPMENTS, 2019-2020
TABLE 198 BMS: KEY FACTS, 2020
TABLE 199 BMS: NUTRITIONAL’S SEGMENT REVENUE ($ MN), 2015-2019
TABLE 200 BMS: STRATEGIC DEVELOPMENTS, 2019
TABLE 201 GILEAD SCIENCES, INC.: KEY FACTS, 2020
TABLE 202 GILEAD SCIENCES: REVENUE ($ BN), 2015-2019
TABLE 203 GILEAD SCIENCES: STRATEGIC DEVELOPMENTS, 2020
TABLE 204 JCR PHARMACEUTICALS: KEY FACTS, 2020
TABLE 205 JCR PHARMACEUTICALS: REVENUE ($ BN), 2015-2019
TABLE 206 JCR PHARMACEUTICALS: STRATEGIC DEVELOPMENTS, 2018
TABLE 207 KOLON TISSUEGENE, INC.: KEY FACTS, 2020
TABLE 208 KOLON TISSUEGENE, INC.: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 209 MEDIPOST: KEY FACTS, 2020
TABLE 210 MEDIPOST: REVENUE ($ MN), 2017-2019
TABLE 211 MEDIPOST: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 212 NOVARTIS AG: KEY FACTS, 2020
TABLE 213 NOVARTIS AG: REVENUE ($ MN), 2015-2019
TABLE 214 NOVARTIS AG: STRATEGIC DEVELOPMENTS, 2018-2020
TABLE 215 ORGANOGENESIS HOLDINGS, INC.: KEY FACTS, 2020
TABLE 216 ORGANOGENESIS: REVENUE ($ TH), 2017-2019
TABLE 217 PHARMICELL CO. LTD.: KEY FACTS, 2020
TABLE 218 SPARK THERAPEUTICS: KEY FACTS, 2020
TABLE 219 SPARK THERAPEUTICS: STRATEGIC DEVELOPMENTS, 2018-2019
TABLE 220 UNIQURE N.V.: KEY FACTS, 2020
TABLE 221 UNIQURE N.V.: REVENUE ($ TH), 2015-2019
TABLE 222 UINQURE N.V.: STRATEGIC DEVELOPMENTS, 2018-2019
TABLE 223 VERICEL CORPORATION: KEY FACTS, 2020
TABLE 224 VERICEL CORPORATION: REVENUE ($ TH), 2015-2019
TABLE 225 VERICEL CORPORATION: STRATEGIC DEVELOPMENTS, 2018
TABLE 226 GLOBAL ATMP: MARKET REVENUE AND FORECAST ($ BN), CAGR (%), 2021, 2026 AND 2031
List of Figures
FIGURE 1 GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS MARKET SEGMENTATION, 2020
FIGURE 2 MARKET DYNAMICS: GLOBAL ATMP MARKET
FIGURE 3 ATMP CLINICAL TRIALS FOR RARE DISEASES BY INDICATION, 2020
FIGURE 4 STEP ANALYSIS: GLOBAL ATMP MARKET, 2020-2031
FIGURE 5 SUPPLY CHAIN: GLOBAL ATMP MARKET
FIGURE 6 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V-SHAPED RECOVERY MODEL)
FIGURE 7 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U-SHAPED RECOVERY MODEL)
FIGURE 8 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L-SHAPED RECOVERY MODEL)
FIGURE 9 GLOBAL ATMP MARKET SCENARIO AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L-SHAPED RECOVERY MODEL)
FIGURE 10 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), 2020-2031
FIGURE 11 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), 2021, 2026 AND 2031 (V-SHAPED RECOVERY MODEL)
FIGURE 12 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 13 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), 2021, 2026 AND 2031 (L - SHAPED RECOVERY MODEL)
FIGURE 14 GLOBAL ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUES ($ BN), 2021, 2026 AND 2031 (W SHAPED RECOVERY MODEL)
FIGURE 15 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031
FIGURE 16 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 17 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
FIGURE 18 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
FIGURE 19 GLOBAL CELL THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (W SHAPED RECOVERY MODEL)
FIGURE 20 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031
FIGURE 21 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (V SHAPED RECOVERY MODEL)
FIGURE 22 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (U SHAPED RECOVERY MODEL)
FIGURE 23 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
FIGURE 24 GLOBAL GENE THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (W SHAPED RECOVERY MODEL)
FIGURE 25 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), AND 2020-2031
FIGURE 26 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (V SHAPED RECOVERY MODEL)
FIGURE 27 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
FIGURE 28 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (L SHAPED RECOVERY MODEL)
FIGURE 29 GLOBAL CAR-T THERAPY PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
FIGURE 30 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031
FIGURE 31 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (V - SHAPED RECOVERY MODEL)
FIGURE 32 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (U - SHAPED RECOVERY MODEL)
FIGURE 33 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (L - SHAPED RECOVERY MODEL)
FIGURE 34 GLOBAL TISSUE ENGINEERED PRODUCTS MARKET AND FORECAST: REVENUES ($ BN) AND AGR (%), 2020-2031 (W - SHAPED RECOVERY MODEL)
FIGURE 35 GLOBAL ATMP MARKET AND FORECAST: BY REGION, REVENUES ($ BN), 2021, 2026 AND 2031
FIGURE 36 GLOBAL ATMP MARKET FORECAST: MARKET SHARE (%), BY REGION, 2021, 2026 AND 2031
FIGURE 37 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), 2021, 2026 AND 203131 (V – SHAPED RECOVERY MODEL)
FIGURE 38 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 39 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), 2021, 2026 AND 2031 (L – SHAPED RECOVERY MODEL)
FIGURE 40 GLOBAL ATMP MARKET AND FORECAST BY REGION, REVENUE ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 41 NORTH AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031
FIGURE 42 NORTH AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (V – SHAPED RECOVERY MODEL)
FIGURE 43 NORTH AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 44 NORTH AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (L – SHAPED RECOVERY MODEL)
FIGURE 45 NORTH AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 46 NORTH AMERICA ATMP MARKET AND FORECAST, BY COUNTRY: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 47 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (V – SHAPED RECOVERY MODEL)
FIGURE 48 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (U – SHAPED MARKET RECOVERY MODEL)
FIGURE 49 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (L – SHAPED RECOVERY MODEL)
FIGURE 50 NORTH AMERICA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 51 U.S. ATMP MARKET AND FORECAST: REVENUE ($ BN), AND AGR (%), 2020-2031
FIGURE 52 U.S. ATMP MARKET AND FORECAST: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 53 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 54 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 55 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 56 U.S. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 57 CANADA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031 131
FIGURE 58 CANADA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 59 CANADA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 60 CANADA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 61 CANADA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 62 CANADA ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 63 EUROPE ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 64 EUROPE ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES HEALTHCARE ($ BN), 2021, 2026 AND 2031 (V – SHAPED RECOVERY MODEL)
FIGURE 65 EUROPE ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 66 EUROPE ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (L – SHAPED RECOVERY MODEL)
FIGURE 67 EUROPE ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 68 EUROPE ATMP MARKET AND FORECAST, BY COUNTRY: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 69 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (V – SHAPED RECOVERY MODEL)
FIGURE 70 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 71 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (L – SHAPED RECOVERY MODEL)
FIGURE 72 EUROPE ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 73 GERMANY ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 74 GERMANY ATMP MARKET AND FORECAST BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 75 GERMANY ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 76 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 77 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 78 GERMANY ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 79 U.K. ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 80 U.K. ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 81 U.K. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 82 U.K. ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 83 U.K. ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 84 U.K. ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 85 FRANCE ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 86 FRANCE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 87 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 88 FRANCE ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 89 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 90 FRANCE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 91 ITALY ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 92 ITALY ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 93 ITALY ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 94 ITALY ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 95 ITALY ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 96 ITALY ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 97 SPAIN ATMP MARKET AND FORECAST: REVENUE ($ MN) AND AGR (%), 2020-2031
FIGURE 98 SPAIN ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 99 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 100 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 101 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 102 SPAIN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 103 REST OF EUROPE ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 104 REST OF EUROPE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 105 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 106 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 107 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 108 REST OF EUROPE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 109 ASIA-PACIFIC ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 110 ASIA-PACIFIC ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (V – SHAPED RECOVERY MODEL)
FIGURE 111 ASIA-PACIFIC ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 112 ASIA-PACIFIC ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (L – SHAPED RECOVERY MODEL)
FIGURE 113 ASIA-PACIFIC ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 114 ASIA-PACIFIC ATMP MARKET AND FORECAST: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 115 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (V – SHAPED RECOVERY MODEL)
FIGURE 116 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 117 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (L – SHAPED RECOVERY MODEL)
FIGURE 118 ASIA-PACIFIC ATMP MARKET AND FORECAST BY COUNTRY, REVENUE ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 119 JAPAN ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 120 JAPAN ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 121 JAPAN ATMP MARKET AND FORECAST REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 122 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 123 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 124 JAPAN ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 125 CHINA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 126 CHINA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 127 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 128 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 129 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 130 CHINA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 131 INDIA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 132 INDIA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 133 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 134 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 135 INDIA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 136 INDIA ATMP MARKET AND FORECAST, ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 137 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 138 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN) 2021, 2026 AND 2031
FIGURE 139 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 140 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 141 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 142 REST OF ASIA-PACIFIC ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 143 LATIN AMERICA ATMP MARKET AND FORECAST: BY THERAPY PRODUCT, REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 144 LATIN AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (V – SHAPED RECOVERY MODEL)
FIGURE 145 LATIN AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 146 LATIN AMERICA ATMP MARKET AND FORECAST BY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (L – SHAPED RECOVERY MODEL)
FIGURE 147 LATIN AMERICA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 148 LATIN AMERICA ATMP MARKET AND FORECAST: BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 149 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 2031 (V – SHAPED RECOVERY MODEL)
FIGURE 150 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 151 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 20311 (L – SHAPED RECOVERY MODEL)
FIGURE 152 LATIN AMERICA ATMP MARKET AND FORECAST, BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 153 BRAZIL ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 154 BRAZIL ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 155 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 156 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 157 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 158 BRAZIL ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 159 MEXICO ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 160 MEXICO ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 161 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 162 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 163 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 164 MEXICO ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 165 REST OF LATIN AMERICA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 166 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 167 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 168 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 169 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 170 REST OF LATIN AMERICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 171 MEA ATMP MARKET AND FORECAST: BY THERAPY PRODUCTS, REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 172 MEA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (V – SHAPED RECOVERY MODEL)
FIGURE 173 MEA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 174 MEA ATMP MARKET AND FORECAST BY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (L – SHAPED RECOVERY MODEL)
FIGURE 175 MEA ATMP MARKET AND FORECAST BY THERAPY PRODUCT: REVENUES ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 176 MEA ATMP MARKET AND FORECAST: BY COUNTRY REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 177 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), 2021, 2026 AND 2031 (V – SHAPED RECOVERY MODEL)
FIGURE 178 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), 2021, 2026 AND 2031 (U – SHAPED RECOVERY MODEL)
FIGURE 179 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), 2021, 2026 AND 2031 (L – SHAPED RECOVERY MODEL)
FIGURE 180 MEA ATMP MARKET AND FORECAST, REVENUE ($ BN), 2021, 2026 AND 2031 (W – SHAPED RECOVERY MODEL)
FIGURE 181 UAE ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 182 UAE ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN) 2021, 2026 AND 2031
FIGURE 183 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 184 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 185 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 186 UAE ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 187 SOUTH AFRICA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 188 SOUTH AFRICA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 189 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 190 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 191 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 192 SOUTH AFRICA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 193 REST OF MEA ATMP MARKET AND FORECAST: REVENUE ($ BN) AND AGR (%), 2020-2031
FIGURE 194 REST OF MEA ATMP MARKET AND FORECAST, BY THERAPY PRODUCTS: REVENUE ($ BN), 2021, 2026 AND 2031
FIGURE 195 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (V – SHAPED RECOVERY MODEL)
FIGURE 196 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (U – SHAPED RECOVERY MODEL)
FIGURE 197 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (L – SHAPED RECOVERY MODEL)
FIGURE 198 REST OF MEA ATMP MARKET AND FORECAST, REVENUE ($ BN) AND AGR (%), 2020-2031 (W – SHAPED RECOVERY MODEL)
FIGURE 199 GLOBAL ATMP MARKET SHARE ANALYSIS (VALUE %), 2020
FIGURE 200 BLUEBIRD BIO, INC.: HISTORICAL REVENUE ($ TH), 2015-2019
FIGURE 201 BMS: NUTRITIONAL’S SEGMENT HISTORICAL REVENUE ($ MN), 2015-2019
FIGURE 202 GILEAD SCIENCES: HISTORICAL REVENUE ($ BN), 2015-2019
FIGURE 203 JCR PHARMACEUTICALS: HISTORICAL REVENUE ($ BN), 2015-2019
FIGURE 204 MEDIPOST: HISTORICAL REVENUE ($ MN), 2017-2019
FIGURE 205 NOVARTIS AG: HISTORICAL REVENUE ($ MN), 2015-2019
FIGURE 206 ORGANOGENESIS: HISTORICAL REVENUE ($ TH), 2017-2019
FIGURE 207 UNIQURE N.V.: HISTORICAL REVENUE ($ TH), 2015-2019
FIGURE 208 VERICEL CORPORATION: HISTORICAL REVENUE ($ TH), 2015-2019
FIGURE 209 GLOBAL ATMP: MARKET REVENUE AND FORECAST ($ BN) AND AGR (%), 2020-2031
FIGURE 210 GLOBAL ATMP MARKET, BY THERAPY PRODUCT MARKET SHARE (%), 2021, 2026 AND 2031
FIGURE 211 GLOBAL ATMP MARKET BY REGIONS, MARKET REVENUE ($ BN) 2021, 2026 AND 2031
Companies Profiled in the Report:
Bluebird bio, Inc.
Bristol Myers-Squibb
Gilead Sciences, Inc.
JCR Pharmaceuticals Co. Ltd.
Kolon TissueGene, Inc.
MEDIPOST
Novartis AG
Organogenesis Holdings, Inc.
PHARMICELL Co., Ltd.
Spark Therapeutics, Inc.
uniQure N.V.
Vericel Corporation
List of Companies Mentioned in the Report:
Aspen Global Incorporated
AveXis
Bayer
Bio Tissue Technologies
Biogen
Celgene Corporation
Century Therapeutics
Endocyte
Forty-Seven, Inc.
Fujifilm Cellular Dynamics
Genetix Pharmaceuticals, Inc
GlaxoSmithKline
IFM Tre, Inc.
Integra Lifesciences
Jazz Pharmaceuticals, Inc.
JCR Pharmaceuticals, Co., Ltd
Medidata Solutions
NuTech Medical
NuVasive, Inc.
Orchard Therapeutics, Inc
Osiris Therapeutics, Inc
Roche
Sarepta Therapeutics
SK Bioland
Tango Therapeutics
The Medicines Company
TissueGene, Inc
Tizona Therapeutics, Inc.
Versant Ventures
Zimmer Biomet
List of Organizations:
Alliance of Regenerative medicine
Bill & Melinda Gates Foundation
Centers for Disease Control and Prevention
Children’s Hospital of Philadelphia
Cystic Fibrosis Foundation
European Medical Agency
International Diabetes Federation
Odylia Therapeutics
U.S. Food and Drug Administration
US National Institutes of Health
World Health Organization
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
